13 March 2024An overview of 405nm violet-blue light as a potential pathogen inactivation technology for ex vivo platelet component safety from transfusion-transmitted infectious diseases
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
Transfusion-transmitted infections (TTIs) is a major public health risk for ex vivo platelet concentrates (PCs) stored for transfusion. Current pathogen reduction technologies (PRTs) use chemicals and/or UV light, which are known to impede quality and efficacy of the treated products and potentiate adverse events in transfusion recipients, while mitigating TTIs. Relative to UV light, visible 405-nm violet-blue light is safer and recently studies were initiated to demonstrate the violet-blue light’s potential at a dose of 270 Jcm-2 for reducing microbial contamination in human plasma and platelets, while preserving the survival and recovery functions intact in a SCID mouse model.
C. D. Atreya
"An overview of 405nm violet-blue light as a potential pathogen inactivation technology for ex vivo platelet component safety from transfusion-transmitted infectious diseases", Proc. SPIE PC12822, Photonic Diagnosis, Monitoring, Prevention, and Treatment of Infections and Inflammatory Diseases 2024, PC128220H (13 March 2024); https://doi.org/10.1117/12.3003271
ACCESS THE FULL ARTICLE
INSTITUTIONAL Select your institution to access the SPIE Digital Library.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
The alert did not successfully save. Please try again later.
C. D. Atreya, "An overview of 405nm violet-blue light as a potential pathogen inactivation technology for ex vivo platelet component safety from transfusion-transmitted infectious diseases," Proc. SPIE PC12822, Photonic Diagnosis, Monitoring, Prevention, and Treatment of Infections and Inflammatory Diseases 2024, PC128220H (13 March 2024); https://doi.org/10.1117/12.3003271